I really thought we had gotten over this problem, but an article appearing in a recent report in the Journal of Clinical Oncology indicates that the age old problem that often our doctors fail to supply adequate pain medications to advanced cancer survivors because a fear of drug addiction This attitude still hampers good survivorship [...]
The pharmaceutical company Exelixis has announced that their experimental treatment, cabozantinib has failed the Phase III clinical trial for men with metastatic castration-resistant prostate cancer (mCRPC). In the trial the experimental treatment cabozantinib was compared to the drug prednisone. In the trial known as COMET-1, Cabozantinib, a tyrosine kinase inhibitor, did not meet its primary [...]
I recently was informed that I am to honored with the 2014 Harry Pinchot Award from the Prostate Cancer Research Institute. The award recognizes outstanding dedication and support to the prostate cancer community. I am pleased and flattered to be one of this year's receptients.I have been told that one reason I have received this [...]
Advanced prostate cancer and its treatments has significant impacts on a man’s quality of life (QOL) as well as their perception of their health. It is important to better understand these concerns, especially those currently not captured by the currently available health-related quality of life (HRQL) instruments. In the quest to better understand these concerns [...]
Abiraterone acetate (AA) or Zytiga has demonstrated a survival benefit in the pre-chemotherapy setting for men with advanced prostate cancer that has become castrate resistant (mCRPC). As a result it is in widespread clinical use in the United States prior to the use of chemotherapy with docetaxel. Since its FDA approval post chemotherapy there has [...]